The role of lipid lowering in transplantation

International Journal of Clinical Practice

Volumn 53, Issue 1, 1999, Pages 54-59

  Wierzbicki, A S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; ANTILIPEMIC AGENT; BEZAFIBRATE; CYCLOSPORIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; IMMUNOSUPPRESSIVE AGENT; LIPID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; HYPERLIPIDEMIAS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PANCREAS TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS; TRANSPLANTATION;

EID: 0032971399     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Kannel WB, Castelli WP, Gordon T. McNamara P. Serum cholesterol lipoproteins and risk of coronary heart disease: the Framingham Study. Ann Intern Med 1971:74: 1-12.
2. Neaton JD. Wentworth JP for the Multiple Risk Factor Intervention Group. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Arch Intern Med 1992; 152: 56-64.
3. McMurray JJV. Primary and secondary prevention of coronary heart disease by cholesterol reduction: recent clinical trial data. Br J Cardiol 1996; 3(suppl 1): S12-S19.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1386.
5. The post-coronary artery bypass graft trial investigators. The effect of aggressive cholesterol lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary bypass grafts. N Engl J Med 1997; 336: 153-162.
6. Shepherd J. Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1996; 335: 153-162.
7. Ibels LS, Alfrey AC, Weil R. Hyperlipidaemia in adult, paediatric and diabetic renal transplant recipients. Am J Med 1978: 64: 634-642.
8. Dimney E. Metabolic factors and outcome of organ transplantation. Scand J Urol Nephrol 1994; 159(suppl): 1-74.
9. Pirsch JD, D'Alessandro AM, Sollinger HW et al. Hyperlipidaemia and transplantation: aetiological factors and therapy. J Am Soc Nephrol 1992; 2(suppl): S238-S242.
10. Grone EF, Walli K, Grone HJ et al. The role of lipids in nephrosclerosis and glomerulosclerosis. Atherosclerosis 1994; 107: 1-13.
11. Austin MA, Edwards KL. Small dense low density lipoproteins, insulin resistance syndrome and non-insulin dependent diabetes mellitus. Curr Opin Lipidol 1996; 7: 167-171.
12. Vlassara H. Advanced glycoxidation: a vascular enemy with many faces. In: Jacotot B. Mathe D, Fruchart J-C, Eds. Atherosclerosis XI. Singapore: Elsevier 1998: 97-106.
13. Brown JH, Anwar N. Short CD et al. Serum lipoprotein (a) in renal transplant recipients receiving cyclosporine monotherapy. Nephrol Dialysis Transpl 1993; 8: 863-867.
14. Webb AT, M. Reaveley DA, O'Donnell M et al. Lipid and lipoprotein (a) concentrations in renal transplant patients. Nephrol Dialysis Transpl 1992; 7: 636-641.
15. de Lorgeril M, Dureau G, Boisonnat P et al. Platelet function and composition in heart transplant recipient compared with nontransplanted coronary patients. Arteriosclerosis Thromb Vase Biol 1992; 12: 222-230.
16. Schoonjans K, Staels B, Auwerx J. The role of the peroxisome proliferator-activator receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907-925.
17. Vaughn CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-1082.
18. Rossen RD. HMG-CoA reductase inhibitors: a new class of anti-inflammatory drugs? J Am Coll Cardiol 1997; 30: 1218-1219.
19. Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins. JAMA 1998; 279: 1643-1650.
20. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CDI lb expression and CD II lb-dependent adhesion of monocytes to endothelium and reduce adhesiveness of monocytes isolated from patients with hypercholesterolaemia. J Am Coll Cardiol 1997; 30: 1212-1217.
21. Cutts JL, Scallen TJ, Watson J, Bankhust AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139: 550-557.
22. Chakrabarti R, Engelman EG. Inter-relationships between mevalonate metabolism and the mitogenic signalling pathway in T lymphocyte proliferation. J Biol Chem 1991; 266: 12216-122121.
23. Kruezer J, Bader J, Jahn L et al. Chemotaxis of the monocyte line U937: dependence on mevalonate pathway products. Atherosclerosis 1991; 90: 203-209.
24. Tatsuno I, Tanaka T, Oeda T et al. Geranyl-geranylpyrophosphate, a metabolite of mevalonate, regulates the cell cycle progression and DNA synthesis in human lymphocytes. Biochem Biophys Res Commun 1997; 241: 376-382.
25. Muldoon MF, Flory JD, Marsland A et al. Effects of lovastatin on the immune system. Am J Cardiol 1997; 80: 1391-1394.
26. Barbagallo CA, Averna MR, Sparacino V et al. HDL subfractions distribution in renal transplant recipients: lack of evidence of a reduction of HDL2 particles. Nephron 1996; 72: 407-412.
27. Duell PB, Malinow MR. Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol 1997; 8: 28-35.
28. Massy ZA, Chadefaux-Vekemans B, Chevalier A et al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant patients. Nephrol Dialysis Transpl 1994; 9: 1103-1108.
29. Ghanem H, van den Dorpel MA, Weimar W et al. Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int 1996; 49: 488-493.
30. Brick DE, Coupon WL, Firts MR. Steroid-free immunosuppression after renal transplantation. J Am Soc Nephrol 1994; 4(suppl): S10-S16.
31. Ballantyne CM, Podet EJ, Patsch WP et al. Effects of cyclosporin therapy on plasma lipoprotein levels. JAMA 1988; 262: 92-95.
32. Schorn TF, Kleim V. Bojanovski M et al. Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant. Transplant Int 1991; 4: 92-95.
33. Kasiske BL, Tortorice KL, Heim-Duthoy KL et al. The adverse effects of cyclosporin on serum lipids in renal transplant patients. Am J Kidney Dis 1991; 17: 700-707.
34. de Groen PC. Cyclosporin, low density lipoprotein and cholesterol. Maya Clin Proc 1988; 43: 1012-1015.
35. Bittar AE, Ratcliffe PJ, Richardson AJ et al. The prevalence of hyperlipidemia in renal transplant patients, associations with immunosuppressive and anti-hypertensive therapy. Transplantation 1990: 50: 987-992.
36. Hohage H, Arit M. Bruckner D et al. Effects of cyclosporin A and FK506 on lipid metabolism and fibrinogen in kidney transplant recipients. Clin Transplant 1997; 11: 225-230.
37. Hilbrands LB, Demacker PN, Hoitsma A et al. Effects of cyclosporin and prednisolone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5: 2073-2081.
38. McCune TR, Thacker LR, Peters TG et al. Effects of tacrolimus on hyperlipidaemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicentre clinical study. Transplantation 1998; 65: 87-92.
39. Bumgardner GL, Wilson GA, Tso PL et al. Impact of serum lipids on long-term graft and patient survival after renal transplantation. Transplantation 1995; 60: 1418-1421.
40. Grimm H, Tibbell A, Norrlind B et al. Nutrition and the allorejection impact of lipids. Transplant Immunol 1995; 3: 62-67.
41. Tonstad S, Holdaas H, Gorbitz C, Ose L. Is dietary intervention effective in post-transplant hyperlipidemia? Nephrol Dialysis Transplant 1995; 10: 82-85.
42. Tzanatos H, Koutsikoks D. Agroyannis B et al. Lipid-lowering effects and safety of acipimox in haemodialysis patients and renal transplant recipients. Renal Failure 1994; 156: 391-405.
43. Yoshimura N, Oka T, Okamoto M, Ohmori Y. The effects of pravastatin on hyperlipidaemia in renal transplant recipients. Transplantation 1992; 53: 94-99.
44. Castro R, Queiros J, Fonseca I et al. Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil. Nephrol Dialysis Transplant 1997; 12: 2140-2143.
45. Castelao AM, Grimo JM, Gilvener S et al. HMG-CoA reductase inhibitors lovastatin and simvastatin in the treatment of hyperlipidaemia after renal transplantation. Transplant Proc 1993; 25: 1043-1048.
46. Locsey L, Asztalso L, Kincses Z, Balazs G. Fluvastatin (Lescol) treatment of hyperlipidemia in patients with renal transplants. Int Urol Nephrol 1997; 29: 95-106.
47. Katznelson S, Wilkinson AH, Kobashigowa JA et al. The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation 1996; 61: 1469-1474.
48. Stein EA, Lane M. Laskarzewski P. Comparison of statins in hypertriglyceridaemia. Am J Cardiol 1998; 81: 66B-69B.
49. Wanner C, Bartens W, Galle J. Clinical utility of anti-lipidaemic therapies in chronic renal allograft failure. Kidney Int 1995; 52(suppl): S60-S62.
50. Katznelson S. The effect of HMG-CoA reductase inhibitors on chronic allograft rejection. Contributions Nephrol 1997; 120: 97-104.
51. Kemna MS, Valantine HA, Hunt SA et al. Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J 1994; 128: 68-72.
52. Rudas L, Pflugfelder PW, McKenzie FN et al. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol 1990; 66: 1135-1138.
53. Atger V, Cambillayu M, Guillemain R et al. Scrum lipid abnormalities in heart transplant recipients: predominance of HDL2 like particles in the HDL pattern. Atherosclerosis 1990; 81: 103-110.
54. Park JW, Merz M, Braun P. Vermelfort M. Lipid disorder and transplant coronary artery disease in longterm survivors of heart transplantation. J Heart Lung Transplant 1996; 15: 572-579.
55. McManus BM, Horley JKJ, Wislon JE et al. Prominence of coronary arterial wall lipids in human heart allografts: implications for pathogenesis of allograft arteriopathy. Am J Pathol 1995; 147: 293-308.
56. Erdoes LS, Hunter GC, Venerus BJ et al. Prospective evaluation of peripheral vascular disease in heart transplant recipients. J Vase Surg 1995; 22: 434-440.
57. Barbir M, Kushwahah S, Hunt B et al. Lipoprotein (a) and accelerated coronary heart disease in cardiac transplant recipients. Lancet 1992; 340: 1500-1502.
58. Parameshar J. Foote J, Sharples L. Lipids, lipoprotein (a) and coronary artery disease in patients following cardiac transplantation. Transplant Int 1996; 9: 481-485.
59. Gupta A, Moustapha A, Jacobsne DW et al. High homocysteine, low folate and low vitamin B6 concentrations. Transplantation 1997; 65: 544-550.
60. Perez-Jimenez F, Hidalgo L, Zambrana JL et al. Comparison of lovastatin and bezafibrate on lipoprotein (a) plasma levels in cardiac transplant recipients. Am J Cardiol 1995; 75: 648-650.
61. Boissonnat P, Salen P, Guidollet J, Ferrera R, Dureau G, Ninet J, Renaud S, de Lorgeril M. The long-term effects of lipid lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation 1994; 58: 245-247.
62. Kobashigawa JA, Murphy FL, Stevenson LW et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82(suppl 4): IV-281.
63. Pflugfelder PW, Huff M, Oskains R et al. Cholesterol-lowering therapy after heart transplantation: a 12 month randomised trial. J Heart Lung Transplant 1995; 14: 613-622.
64. Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.
65. Wenke K, Meiser B, Thiery J et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation 1997; 96: 1398-1402.
66. Southworth MR, Mauro VF. The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients. Ann Pharmacother 1997; 31: 489-491.
67. Abbasoglu O, Levy MF, Brkic BB et al. Ten years of liver transplants. Transplantation 1997; 64: 1801-1807.
68. Miller LW. Allograft vascular disease: a disease not limited to hearts. J Heart Lung Transplant 1992; 11: s32-s36.
69. McDiarmid SV, Gornbein JA, Fortuany M et al. Serum lipid abnormalities in paediatric liver transplant patients. Transplantation 1992; 53: 109-115.
70. Krentz AJ, Cramb R, Dousset B et al. Serum lipids and apolipoproteins in liver transplant recipients: a comparative study of cyclosporin A and FK506. J Lab Clin Med 1994; 124: 381-385.
71. Jinnal RM, Popescu I, Emre S et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporin versus FK506. Transplantation 1994; 57: 1395-1398.
72. Cazannello VJ, Schwartz L, Taler SJ et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporin A and tacrolimus (FK506). Liver Transplant Surg 1997; 3: 1-9.
73. McDiarmid SV, Farmer DA, Goldstein LI et al. A randomised prospective trial of steroid withdrawal after liver transplantation. Transplantation 1995; 60: 1443-1450.
74. Imagawa DK, Dawson S, Holt CD et al. Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methyl-glutaryl-coenzyme A reductase inhibitor pravastatin. Transplantation 1996; 62: 934-942.
75. Foger B, Konigsrainer A, Palos G et al. Effect of pancreas transplantation on lipoprotein lipase, postprandial lipaemia and HDL cholesterol. Transplantation 1994; 58: 899-904.
76. Arita S, Kasraie A, Une S et al. Pravastatin and lowdose cyclosporin treatment prevent islet allograft rejection in mice. Transplant Proc 1998; 30: 522-526.
77. Kobashigawa JA, Kasiske BL, Hyperlipidemia in solid organ transplants. Transplantation 1997; 63: 331-338.
78. Arnadottir M, Berg A-L. Treatment of hyperlipidaemia in renal transplant recipients. Transplantation 1997; 63: 339-345.